Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Stock Information for Moleculin Biotech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Moleculin Biotech Inc.

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Moleculin to Present at 38th Annual ROTH Conference
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
Moleculin Launches CEO Corner Platform to Share Strategic Insights
Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects 

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.